May 18, 2012
1 min read
Save

Circulating visfatin levels may predict ROP development

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Circulating levels of visfatin in preterm infants may serve as a predictive marker for retinopathy of prematurity, according to a study.

Eighty-eight infants born between 2007 and 2009 with a gestational age younger than 32 weeks were included in the study.

The study group comprised 14 infants who were diagnosed with ROP stages 3 to 5 and a control group of 74 infants without ROP. The researchers collected fetal cord blood and a blood sample at 4 to 6 weeks postnatal age for laboratory analysis of visfatin and insulin-like growth factor 1 (IGF-1) levels.

Results showed that infants without ROP had higher visfatin-1, visfatin-2, insulin-1, insulin-2, (IGF-1)-1, and (IGF-1)-2 levels compared to those who had ROP (P < .001 for all levels).

Change in visfatin was positively correlated with change in IGF-1 and insulin, and change in IGF-1 was positively correlated with change in insulin. No significant differences were found in terms of birth weight or gestational age.

“We believe that similar to IGF-1 levels and weight gain, the measurement of visfatin levels can be used as a predictive marker in determining which infants will develop ROP. However, further longitu­dinal studies including a larger number of cases are needed about this subject,” the researchers said.